Abstract:Objective To investigate the protective effects of 2-methoxyestradiol (2ME) against hypoxic pulmonary hypertension (HPH) in neonatal rats. Methods Ninety-six Wistar neonatal rats were randomly divided into a normoxia group, a hypoxia group, and a hypoxia + 2ME group, with each group further subdivided into 3-day, 7-day, 14-day, and 21-day subgroups, containing eight rats each. The hypoxia and hypoxia + 2ME groups received daily subcutaneous injections of saline and 2ME (240 μg/kg), respectively, while the normoxia group was raised in a normoxic environment with daily saline injections. Right ventricular systolic pressure (RVSP) was measured using the direct pressure method. Pulmonary vascular morphology was assessed using hematoxylin and eosin staining, with metrics including the percentage of medial thickness of small pulmonary arteries relative to the external diameter (MT%) and the cross-sectional area of the media of small pulmonary arteries relative to the total cross-sectional area (MA%). Immunohistochemistry was used to detect the expression levels of hypoxia-inducible factor-1α (HIF-1α) and proliferating cell nuclear antigen (PCNA) proteins, while real-time quantitative PCR was used to to assess HIF-1α and PCNA mRNA levels. Results Compared to the normoxia group, the hypoxia and hypoxia + 2ME groups showed increased RVSP and upregulated HIF-1α and PCNA protein and mRNA expression levels at 3, 7, 14, and 21 days after hypoxia (P<0.05). Furthermore, at 7, 14, and 21 days after hypoxia, the hypoxia group showed increased MT% and MA% (P<0.05). In comparison to the hypoxia group, the hypoxia + 2ME group exhibited reduced RVSP and downregulated HIF-1α and PCNA protein and mRNA expression levels, along with decreased MT% and MA% at 7, 14, and 21 days after hypoxia (P<0.05). Conclusions 2ME may protect against HPH in neonatal rats by inhibiting the expression of HIF-1α and PCNA and reducing pulmonary vascular remodeling. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 757-764
XIE Ou,LI Shan-Shan,LUO Yang et al. Protective effects of 2-methoxyestradiol against hypoxic pulmonary hypertension in neonatal rats[J]. CJCP, 2024, 26(7): 757-764.
Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn[J]. Pediatr Pulmonol, 2021, 56(3): 661-669. PMID: 32930508. DOI: 10.1002/ppul.25073.
Zahid KR, Raza U, Chen J, et al. Pathobiology of pulmonary artery hypertension: role of long non-coding RNAs[J]. Cardiovasc Res, 2020, 116(12): 1937-1947. PMID: 32109276. DOI: 10.1093/cvr/cvaa050.
Awad KS, West JD, de Jesus Perez V, et al. Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series)[J]. Pulm Circ, 2016, 6(3): 285-294. PMID: 27683605. PMCID: PMC5019081. DOI: 10.1086/688034.
Huang N, Zhu TT, Liu T, et al. Aspirin ameliorates pulmonary vascular remodeling in pulmonary hypertension by dampening endothelial-to-mesenchymal transition[J]. Eur J Pharmacol, 2021, 908: 174307. PMID: 34245748. DOI: 10.1016/j.ejphar.2021.174307.
Cao J, Yang L, Wang L, et al. Heat shock protein 70 attenuates hypoxia?induced apoptosis of pulmonary microvascular endothelial cells isolated from neonatal rats[J]. Mol Med Rep, 2021, 24(4): 690. PMID: 34328190. PMCID: PMC8365595. DOI: 10.3892/mmr.2021.12327.
Montalva L, Antounians L, Zani A. Pulmonary hypertension secondary to congenital diaphragmatic hernia: factors and pathways involved in pulmonary vascular remodeling[J]. Pediatr Res, 2019, 85(6): 754-768. PMID: 30780153. DOI: 10.1038/s41390-019-0345-4.
Hao S, Jiang L, Fu C, et al. 2-Methoxyestradiol attenuates chronic-intermittent-hypoxia-induced pulmonary hypertension through regulating microRNA-223[J]. J Cell Physiol, 2019, 234(5): 6324-6335. PMID: 30246291. DOI: 10.1002/jcp.27363.
Docherty CK, Nilsen M, MacLean MR. Influence of 2-methoxyestradiol and sex on hypoxia-induced pulmonary hypertension and hypoxia-inducible factor-1-α[J]. J Am Heart Assoc, 2019, 8(5): e011628. PMID: 30819028. PMCID: PMC6474940. DOI: 10.1161/JAHA.118.011628.
Tofovic SP, Salah EM, Mady HH, et al. Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats[J]. J Cardiovasc Pharmacol, 2005, 46(4): 430-437. PMID: 16160593. DOI: 10.1097/01.fjc.0000175878.32920.17.
Enazy SA, Kirschen GW, Vincent K, et al. PEGylated polymeric nanoparticles loaded with 2-methoxyestradiol for the treatment of uterine leiomyoma in a patient-derived xenograft mouse model[J]. J Pharm Sci, 2023, 112(9): 2552-2560. PMID: 37482124. PMCID: PMC10529399. DOI: 10.1016/j.xphs.2023.07.018.
Yu C, Li C, Pan H, et al. Preparation of 2-methoxyestradiol self-emulsified drug delivery system and the effect on combination therapy with doxorubicin against MCF-7/ADM cells[J]. AAPS PharmSciTech, 2022, 23(5): 147. PMID: 35585431. DOI: 10.1208/s12249-022-02298-6.
Wang L, Zheng Q, Yuan Y, et al. Effects of 17β-estradiol and 2-methoxyestradiol on the oxidative stress-hypoxia inducible factor-1 pathway in hypoxic pulmonary hypertensive rats[J]. Exp Ther Med, 2017, 13(5): 2537-2543. PMID: 28565876. PMCID: PMC5443199. DOI: 10.3892/etm.2017.4243.
Kumar S, Vaidya M. Hypoxia inhibits mesenchymal stem cell proliferation through HIF1α-dependent regulation of P27[J]. Mol Cell Biochem, 2016, 415(1/2): 29-38. PMID: 26920732. DOI: 10.1007/s11010-016-2674-5.